PCI – 7th June 2024
Thermofisher: Thu 29 February 2024, 11:15

Current Edition

Upcoming Events

PEGS Boston
ELRIG Drug Discovery USA
ELRIG Cell and Gene Therapy 18.02.25
Biotechnology Show 13.02.26
NexGen Biomed 23.01.25
PFS & Injectable drug devices west coast
PFS & Injectable Drug Devices East Cost
AI in Drug Discovery
Bio Trinity
Anglo Nordic

Advertisement

A&M STABTEST: Fri 21 June 2024, 11:43
CDD Vault – 18.03.2025
Biopharma Group – 19th March 2025
Light Cast – 17.07.2025
QMB Innovation Centre

Astoriom Appoints Will Edwards as Chief Executive Officer

Strategic appointment to support global scale-up of sample management operations

Astoriom, a global quality expert in safeguarding scientific research and consumer product sample assets, today announced the appointment of Will Edwards as Chief Executive Officer. Will will continue to build on Astoriom’s strong foundations to support the next phase of growth across its international portfolio of sample stability storage, biorepository services, validation solutions, as well as sample storage design and disaster recovery. His appointment reflects Astoriom’s continued focus on operational excellence, resilience and scaling high-quality, compliant sample management solutions for organizations operating in complex, regulated life science and consumer product environments. He succeeds Lori A. Ball, who has decided to transition into a board seat.

Will brings extensive international leadership experience in the storage, logistics and technology sectors, most recently as CEO of Spectrum Storage Group. With a customer-focused, data-driven approach honed at global companies, including Google and Bain & Co, he has led businesses through periods of rapid growth and operational transformation over the last two decades. Will holds an MBA from INSEAD and an MS from Stanford University.

Will’s appointment comes at a pivotal moment for Astoriom, as demand continues to grow for outsourced, resilient, and compliant sample management and storage solutions to protect high-value research and product samples across pharmaceutical, biotechnology, medical device, and consumer product sectors worldwide. His experience leading complex storage operations and scaling service-led platforms will support Astoriom’s ambition to continue to expand internationally, working with global life science organizations, while maintaining the highest standards of quality, compliance, and customer trust.

Mark Hammond, Chairman at Astoriom, said: “Astoriom plays a critical role in protecting high-value scientific and product assets for customers operating in regulated environments. Will’s expertise scaling international companies in the storage sector and beyond is remarkable and will be instrumental in realizing the company’s full potential. His appointment reflects our confidence in his ability to lead the business through its next phase of growth, while maintaining the operational rigour, quality standards, and customer trust that define Astoriom’s proposition.

We’d also like to thank outgoing CEO, Lori A. Ball for her dedicated leadership and look forward to continuing to work alongside her as she joins Astoriom’s board.”

Lori A. Ball, outgoing CEO and Board Member of Astoriom, said: “Astoriom has reached an important inflection point in its growth journey. Will brings the leadership experience, strategic mindset, and operational discipline required to guide the business through its next phase of global expansion. I am confident he will build on the strong foundations in place and continue to strengthen Astoriom’s position as a trusted partner for organizations that depend on the integrity and protection of their sample assets.”

Will Edwards, CEO of Astoriom, said: “Astoriom has built a strong reputation as a global industry leader for quality, reliability, and technical excellence in a sector where trust and resilience are essential. The business has grown significantly in the last couple of years and is at an exciting stage of development. The team is committed to providing accessible stability storage and biorepository solutions to safeguard the integrity and viability of valuable sample assets; I look forward to working with them to continue to scale capabilities worldwide, while remaining firmly focused on compliance, operational excellence, and long-term customer partnerships.”

For more information about Astoriom and its leadership team, please visit: https://www.astoriom.com/about/  

The Bridge 28.01
Newcells 3 June 2024, 15:12
Aldevron: 16th January 2025
Richter: Wed 23 October 2024, 09:03
Asychem – 10.04.2025
Taconic Biosciences – 29.04.25
Steribar – 12.05.2025
Crown Bioscience 08.09.2025
Polypure hompage